James G. Ham
Nessuna posizione attualmente
Profilo
James G.
Ham worked as Vice President-Information Technology at Bristol Myers Squibb Co. from 1994 to 2001.
He then worked as Chief Financial Officer, Secretary, Treasurer & VP at NitroMed, Inc. from 2004 to 2008.
From 2008 to 2013, he served as Chief Financial Officer at Inotek Pharmaceuticals Corp.
He also worked as Vice President-Finance at Infinity Pharmaceuticals, Inc. and as Chief Financial Officer at Clearview Group.
Mr. Ham holds an MBA degree from St. John's University and an undergraduate degree from Villanova University.
Precedenti posizioni note di James G. Ham
| Società | Posizione | Fine |
|---|---|---|
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Direttore Finanziario/CFO | 01/01/2013 |
NitroMed, Inc.
 NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Direttore Finanziario/CFO | 11/04/2008 |
| BRISTOL-MYERS SQUIBB COMPANY | Direttore Tecnico/Scientifico/R&S | 01/01/2001 |
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Clearview Group
 Clearview Group Miscellaneous Commercial ServicesCommercial Services Clearview Group provides strategic management services. The private company is based in Miller Place, NY. The company was founded by Shamez Kanji. | Direttore Finanziario/CFO | - |
Formazione di James G. Ham
| Villanova University | Undergraduate Degree |
| St. John's University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Health Technology |
Clearview Group
Clearview Group Miscellaneous Commercial ServicesCommercial Services Clearview Group provides strategic management services. The private company is based in Miller Place, NY. The company was founded by Shamez Kanji. | Commercial Services |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- James G. Ham